Interaction between the Number of Chemotherapy Cycles and Brachytherapy Dose/Volume Parameters in Locally Advanced Cervical Cancer Patients.
chemoradiation
chemotherapy
image-guided adaptive brachytherapy
locally advanced cervical cancer
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
01 Jun 2020
01 Jun 2020
Historique:
received:
24
04
2020
revised:
15
05
2020
accepted:
26
05
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
5
6
2020
Statut:
epublish
Résumé
Scarce data exist on concurrent chemotherapy in locally advanced cervical cancer (LACC) patients (pts) treated with image-guided adaptive brachytherapy (IGABT). We examined the effect of a number of chemotherapy cycles and their interaction with brachytherapy dose/volume parameters. Clinical records of 209 consecutive pts treated for a LACC were reviewed. Pts received CRT concurrently with cisplatin 40 mg/m² or carboplatin AUC2. An additional cycle could have been delivered during the pulse-dose rate (PDR)-IGABT. The impact of a number of chemotherapy cycles on outcome was examined, as well as the interactions with dose volume parameters. The number of cycles was four in 55 (26.3%) pts, five in 154 (73.7%) including 101 receiving the fifth cycle during IGABT. Median follow-up was 5.5 years. Pts receiving five cycles had a better outcome on all survival endpoints, including three year local control rate (93.9% vs. 77.2%;
Identifiants
pubmed: 32492777
pii: jcm9061653
doi: 10.3390/jcm9061653
pmc: PMC7356737
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2008 Dec 10;26(35):5802-12
pubmed: 19001332
Oncotarget. 2016 Nov 15;7(46):74886-74894
pubmed: 27713124
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):133-9
pubmed: 18774656
Brachytherapy. 2010 Jul-Sep;9(3):274-7
pubmed: 20153985
Radiother Oncol. 2011 Jul;100(1):116-23
pubmed: 21821305
N Engl J Med. 1999 Apr 15;340(15):1154-61
pubmed: 10202166
Radiother Oncol. 2012 Jun;103(3):305-13
pubmed: 22633469
N Engl J Med. 1999 Apr 15;340(15):1137-43
pubmed: 10202164
Eur Arch Otorhinolaryngol. 2017 Oct;274(10):3757-3765
pubmed: 28755023
Gynecol Oncol. 2014 May;133(2):256-62
pubmed: 24517875
Gynecol Oncol. 2017 May;145(2):374-385
pubmed: 28188016
J Clin Oncol. 1999 May;17(5):1339-48
pubmed: 10334517
N Engl J Med. 1999 Apr 15;340(15):1144-53
pubmed: 10202165
Brachytherapy. 2016 Sep-Oct;15(5):537-42
pubmed: 27371991
Brachytherapy. 2016 Jul-Aug;15(4):456-462
pubmed: 27180129
Radiother Oncol. 2015 Feb;114(2):257-63
pubmed: 25497872
J Clin Oncol. 2002 Feb 15;20(4):966-72
pubmed: 11844818
Radiother Oncol. 2016 Sep;120(3):428-433
pubmed: 27134181
Radiother Oncol. 2013 Apr;107(1):69-74
pubmed: 23639580
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD008285
pubmed: 20091664
Acta Oncol. 2013 Oct;52(7):1510-9
pubmed: 23962242
J Clin Oncol. 2006 Jun 10;24(17):2612-7
pubmed: 16763273
Nat Clin Pract Oncol. 2007 Feb;4(2):86-100
pubmed: 17259930
CA Cancer J Clin. 2019 Sep;69(5):386-401
pubmed: 31361333
N Engl J Med. 1999 Apr 15;340(15):1198-200
pubmed: 10202172
Radiother Oncol. 2009 Nov;93(2):311-5
pubmed: 19679365